GLASGOW 2018
Learn more
OUR MEDICINES
LEARN MOREIn the management of HIV, times are changing
Are your treatment decisions for your virologically suppressed patients changing with them?
LEARN MORE ABOUT 2DRThe first single-pill, 2-drug regimen for your virologically suppressed patients.
LEARN MORELatest Videos
Our medicines
JULUCA▼
JULUCA (dolutegravir/rilpivirine) is indicated for HIV-1 virologically suppressed adults on a stable regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.
TRIUMEQ▼
TRIUMEQ (dolutegravir/abacavir/lamivudine) is indicated for the treatment of HIV-infected adults and adolescents above 12 years of age weighing at least 40 kg.
TIVICAY▼
TIVICAY (dolutegravir) is indicated in combination with other antiretroviral medicinal products for the treatment of HIV-infected and adolescents above 12 years of age.
CELSENTRI
CELSENTRI (maraviroc) is indicated in combination with other antriretroviral medicinal products for treatment-experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only CCR5-tropic HIV-1 detectable.
UK/DTGP/0002/17(7) | October 2018